Pharma Industry Unites With Academia to Tackle Ongoing Problem

LONDON, October 28, 2011 /PRNewswire/ --

Leading academic and industry specialists to meet in Amsterdam next February to discuss the challenges that could see R&D grind to a halt and the newest ways to tackle them

Selecting and screening the correct polymorphs and ensuring the characterisation of the co-crystals in the most efficient and effective way has never been more vital. According to George Tranter from Chiralabs, "Crystallisation is one of the biggest problems of the pharmaceutical industry".

The 8th Annual Polymorphism and Crystallisation speaker panel will be dedicated to presenting the cutting edge technologies and techniques of getting the pharmaceutical product to the market whilst overcoming the problems of polymorphism.

According to an Engineer article "Co-crystallisation could speed up drug production" (5th September), scientists have started seeking to understand the science behind this process. However, co-crystallisation requires particular attention to considerations like availability and quality of drugs, waste streams generated and batch performance. Pharma IQ's Polymorphism and Crystallisation speakers will provide an insight into these issues live only on 28th and 29th February in Amsterdam. Case studies will be presented by the likes of Eli Lily, UCB Pharma and Novartis-MIT Centre for Continuous Manufacturing, and a fantastic interactive workshop will be run by an EPO representative.

Pharma IQ's summit will be dedicated to delivering cutting edge insights into areas such as:

  • Best timing and depth for a polymorphic screen during pharmaceutical development
  • Characterisation of co-crystals and selection of tools for correct characterisation tests
  • Polymorphic scale up
  • Application of PAT and QbD in pharmaceutical processes
  • Patenting of new polymorphs

At Polymorphism and Crystallisation, attendees will hear best practices from the big industry names like GlaxoSmithKline, Merck, AstraZeneca, Johnson and Johnson, Continuous Manufacturing and Crystallisation (CMAC), together with leading academic institutions like University of Loughborough, University of Leeds, University of Rouen, and more.

The full agenda, podcast, articles and interviews, are available on:
http://www.polyandcrys.com/PRNW/Event

The LinkedIn Group is open and welcomes anybody in topic and event related discussions:
http://www.linkedin.com/groups?home=&gid=1781786&trk=anet_ug_hm

Find the full program, event details and registration information on Polymorphism and Crystallisation 2012:
Visit: http://www.polyandcrys.com/PRNW/Event
Email [email protected]
Call: +44(0)207-368-9300

Media contact: Gergana Stoyanova
Tel: +44(0)2073689865
email: [email protected]
website: http://www.pharma-iq.com


SOURCE Pharma IQ

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.